The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: Interleukin-17A and interleukin-17F serum levels

Immunology Letters

Volumn 164, Issue 2, 2015, Pages 76-80

  Babaloo, Zohreh ^a,b,c,d   Aliparasti, Mohammad Reza ^a,b,d   Babaiea, Farhad ^b   Almasi, Shohreh ^d   Baradaran, Behzad ^b,d   Farhoudi, Mehdi ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

IL 17A; IL 17F; Multiple Sclerosis; Relapsing remitting MS; Th17

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17F;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION INDEX; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TH17 CELL; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TH17 CELLS; YOUNG ADULT;

EID: 84924587542     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.01.001     Document Type: Article

References (32)

1. McFarlin D.E., McFarland H.F. Multiple sclerosis (first of two parts). N Engl J Med 1982, 307:1183-1188.
2. Nagelkerken L. Role of Th1 and Th2 cells in autoimmune demyelinating disease. Braz J Med Biol Res 1998, 31:55-60.
3. McDonald W.I. Relapse, remission, and progression in multiple sclerosis. N Engl J Med 2000, 343:1486-1487.
4. McFarland H.F., Frank J.A., Albert P.S., Smith M.E., Martin R., Harris J.O., et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992, 32:758-766.
5. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7.
6. Zhang G.X., Gran B., Yu S., Li J., Siglienti I., Chen X., et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003, 170:2153-2160.
7. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002, 110:493-497.
8. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
9. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
10. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205:1063-1075.
11. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain J Neurol 2009, 132:3329-3341.
12. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
13. Jin W., Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013, 2:e60.
14. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
15. Zepp J., Wu L., Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011, 32:232-239.
16. Witowski J., Ksiazek K., Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci CMLS 2004, 61:567-579.
17. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
18. Huppert J., Closhen D., Croxford A., White R., Kulig P., Pietrowski E., et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 2010, 24:1023-1034.
19. Martins T.B., Rose J.W., Jaskowski T.D., Wilson A.R., Husebye D., Seraj H.S., et al. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 2011, 136:696-704.
20. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009, 65:499-509.
21. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
22. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
23. Mesquita D., Cruvinel W.M., Camara N.O., Kallas E.G., Andrade L.E. Autoimmune diseases in the TH17 era. Braz J Med Biol Res 2009, 42:476-486.
24. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
25. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
26. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
27. Hedegaard C.J., Krakauer M., Bendtzen K., Lund H., Sellebjerg F., Nielsen C.H. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008, 125:161-169.
28. Babaloo Z., Babaie F., Farhoodi M., Aliparasti M.R., Baradaran B., Almasi S., et al. Interleukin-17A and interleukin-17F mRNA expression in peripheral blood mononuclear cells of patients with multiple sclerosis. Iran J Immunol 2010, 7:202-209.
29. Haak S., Croxford A.L., Kreymborg K., Heppner F.L., Pouly S., Becher B., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009, 119:61-69.
30. Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J., Das Sarma J., et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007, 179:3268-3275.
31. Deiss A., Brecht I., Haarmann A., Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013, 13:313-335.
32. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmunity Rev 2011, 10:809-810.